Close
Close

Anti-IGRP T cell receptor (17.6α-8.3β), pCDTCR1 (TCR-YC0550)

 Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-IGRP T cell receptor (TCR) is constructed for the engineering of T cell to target IGRP (206-214) variant (KYNKANAFL) restricted by H2-Kᵈ. The T cells are genetically modified through transduction with a lentiviral vector expressing IGRP-specific T cell receptor.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • IGRP
  • Epitope
  • KYNKANAFL
  • Format
  • Non-Modified TCR
  • Allele
  • H2-Kᵈ
  • Targeting Diseases
  • Type 1 diabetes (T1D)
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • 17.6α-8.3β
  • Host Species
  • Mouse

Target

  • Introduction
  • Type 1 diabetes (T1D) in both humans and nonobese diabetic (NOD) mice is a chronic autoimmune disease that results from destruction of pancreatic β cells by CD4+ and CD8+ T cells targeting many antigens. A large fraction of the islet-associated CD8+ cells in NOD mice recognize the mimotopes NRP-A7 and -V7 in the context of the MHC molecule Kd. These T cells are diabetogenic, target a peptide from islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP 206-214, similar to NRP-A7 and -V7), and circulate in the blood, particularly as clinical disease nears. Another important feature of the diabetogenic CD8+ response is that it involves recognition, by smaller T cell pools, of many other IGRP epitopes and epitopes in other, even ubiquitous, autoantigens, such as dystrophia myotonica kinase (DMK). The polyspecificity of this T cell response is compounded by the fact that individual specificities harbor clones engaging pMHC over a range of avidities, the strength of which correlates with pathogenic potential.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-IGRP T cell receptor (17.6α-8.3β), pCDTCR1 (TCR-YC0550). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

TCR Vector Products

Others

Melanoma

Pancreatic cancer

Acute lymphoblastic leukemia (ALL)

Lung malignancy

Prostate cancer

Colorectal cancer

Breast cancer

Autoimmune Diseases

Mature T cell and natural killer (NK) cell neoplasms

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout